Max Healthcare (MAXHEALTH)

FairStock Score: 45/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Strong growth: sales growth 24.44%, profit growth 40.73%, and 5-year revenue CAGR of 22.89%; latest quarter sales ₹2,068 Cr and net profit ₹301 Cr.
• Healthy profitability: ROE 15.13% and ROCE 14.88% indicate efficient capital use.
• Solid financial position: debt/equity 0.33, Altman Z-Score 5.81, and Piotroski F-Score 8/9 suggest low bankruptcy risk.
• High growth visibility from a large hospital network, reflected in consistent operating scale.

Concerns

• Extremely expensive valuation: P/E 72.83, P/B 10.45, and EV/EBITDA 131.82 leave almost no margin of safety.
• Negative free cash flow of ₹-155 Cr despite reported profitability.
• Minimal shareholder yield: dividend yield only 0.14%.
• Promoter holding at 23.72% is relatively low, raising governance and alignment questions.

AI Analysis

At first glance, Max Healthcare tests every ounce of my patience. The business is growing nicely—sales up 24.44%, profit up 40.73%, and a 5-year revenue CAGR of 22.89%—so I accept that this is a fast grower. The latest quarter’s ₹2,068 Cr sales and ₹301 Cr net profit show respectable scale. Return on equity of 15.13% and ROCE of 14.88% are decent, though not mouth-watering for a business selling at 72.83 times earnings. The balance sheet is sound: debt/equity of 0.33, Altman Z-Score of 5.81, and a Piotroski F-Score of 8/9 underline low bankruptcy risk and operational discipline. But the valuation is the problem. I cannot reconcile a price-to-book of 10.45, an EV/EBITDA of 131.82, and a Graham Number of ₹178 with the current price of ₹1,007. That gives a margin of safety of negative 513%. Mr. Market is paying a fortune for future growth that may or may not appear. I also notice free cash flow is negative at ₹-155 Cr; profit is not converting into cash, which is typical for a capital-hungry hospital operator. The 0.14% dividend yield and promoter holding of only 23.72% give me little comfort. Hospital businesses can enjoy genuine moats through location, medical talent, and trust, but these numbers do not yet prove a durable moat sufficient to justify today's price. A great company, if it is great, is not necessarily a great investment at any price. For a disciplined investor, the wise course is to wait, let growth compound, and hope that the price eventually offers a margin of safety. Until then, I would rather be early than foolish.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer